These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9411386)

  • 1. Respiratory syncytial virus PREVENT Study questions.
    Raju TN
    Pediatrics; 1997 Dec; 100(6):1044; author reply 1045. PubMed ID: 9411386
    [No Abstract]   [Full Text] [Related]  

  • 2. Respiratory syncytial virus PREVENT Study questions.
    Moler FW
    Pediatrics; 1997 Dec; 100(6):1043-4; author reply 1045. PubMed ID: 9411385
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection?].
    Greisen G
    Ugeskr Laeger; 2001 Nov; 163(47):6607. PubMed ID: 11760548
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost estimates of prophylaxis.
    Moler F
    Arch Pediatr Adolesc Med; 2001 Feb; 155(2):199-200. PubMed ID: 11177100
    [No Abstract]   [Full Text] [Related]  

  • 5. Respiratory syncytial virus PREVENT Study questions.
    Dransfield D; Kessler D; McCarthy C
    Pediatrics; 1997 Dec; 100(6):1044-5. PubMed ID: 9411387
    [No Abstract]   [Full Text] [Related]  

  • 6. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis for severe respiratory syncytial virus disease.
    Kupecz D
    Nurse Pract; 1996 Sep; 21(9):116-8. PubMed ID: 8884798
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM; Jacobs RF
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A
    Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RSV-IG (respigam).
    Snyder R
    Neonatal Netw; 1998 Apr; 17(3):63-5. PubMed ID: 9601353
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory syncytial virus immune globulin intravenous (human) receives marketing approval in Canada.
    Langley JM
    Can Fam Physician; 1998 Jan; 44():113. PubMed ID: 9481469
    [No Abstract]   [Full Text] [Related]  

  • 14. Respiratory syncytial virus immune globulin and conflict of interest.
    Groothuis JR
    N Engl J Med; 1998 Nov; 339(22):1644. PubMed ID: 9867534
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of local guidelines for prevention of respiratory syncytial viral infections.
    Hall CB; Stevens TP; Swantz RJ; Sinkin RA; McBride JT
    Pediatr Infect Dis J; 1999 Oct; 18(10):850-3. PubMed ID: 10530578
    [No Abstract]   [Full Text] [Related]  

  • 16. The other effect of intravenously administered respiratory syncytial virus-enriched immune globulin for prophylaxis: less acute otitis media.
    Harrison CJ
    J Pediatr; 1996 Aug; 129(2):193-6. PubMed ID: 8765615
    [No Abstract]   [Full Text] [Related]  

  • 17. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab (Synagis) for prevention of RSV infection.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):3-4. PubMed ID: 9924488
    [No Abstract]   [Full Text] [Related]  

  • 19. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.